Table 1.
Summary of baseline patient and disease characteristics for DISCOVER-1 patients by TNFi status
| All patients | TNFi-naive | TNFi-experienced | |
| Randomised and treated patients, N | 381 | 263 (69%) | 118 (31%) |
| Age (years), mean (SD) | 48.4 (11.4) | 47.6 (11.7) | 50.2 (10.5) |
| Sex, n (%) | |||
| Male | 195 (51.2) | 133 (50.6) | 62 (52.5) |
| Female | 186 (48.8) | 130 (49.4) | 56 (47.5) |
| Weight (kg), mean (SD) | 86.0 (18.8) | 86.3 (18.8) | 85.4 (18.7) |
| BMI (kg/m2), mean (SD) | 29.8 (5.8) | 29.8 (6.0) | 29.9 (5.5) |
| Normal (<25), n (%) | 79 (20.7) | 58 (22.1) | 21 (17.8) |
| Overweight (≥25 and<30) | 136 (35.7) | 95 (36.1) | 41 (34.7) |
| Obese (≥30), n (%) | 166 (43.6) | 110 (41.8) | 56 (47.5) |
| PsA disease duration (years), mean (SD) | 6.8 (6.6) | 5.6 (6.2) | 9.4 (6.9) |
| Joint counts, mean (SD) | |||
| Swollen (0–66) | 9.8 (7.6) | 9.5 (7.0) | 10.6 (8.7) |
| Tender (0–68) | 19.3 (14.0) | 17.9 (13.2) | 22.4 (15.3) |
| Psoriasis disease duration (years), mean (SD) | 17.0 (12.7) | 16.4 (13.3) | 18.3 (11.1) |
| Psoriasis, n (%) | |||
| ≥3% BSA | 281 (73.9)* | 191 (72.9)† | 90 (76.3) |
| IGA ≥2 and ≥3% BSA | 249 (65.5)* | 166 (63.4)† | 83 (70.3) |
| HAQ-DI (0–3), mean (SD) | 1.2 (0.6) | 1.1 (0.6) | 1.4 (0.7) |
| CRP (mg/dL), mean (SD) | 1.4 (2.0) | 1.1 (1.8) | 1.9 (2.3) |
| DMARD use at baseline, n (%) | 247 (64.8) | 160 (60.8) | 87 (73.7) |
| Methotrexate | 211 (55.4) | 133 (50.6) | 78 (66.1) |
| Other | 36 (9.4) | 27 (10.3) | 9 (7.6) |
*N=380.
†N=262.
BMI, body mass index; BSA, body surface area; CRP, C reactive protein; DMARD, disease-modifying antirheumatic drug; HAQ-DI, Health Assessment Questionnaire-Disability Index; IGA, Investigator’s Global Assessment of psoriasis; PsA, psoriatic arthritis; TNFi, tumor necrosis factor-inhibitor.